HC Wainwright & Co. Downgrades Fulcrum Therapeutics to Neutral, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has downgraded Fulcrum Therapeutics from Buy to Neutral and reduced the price target from $17 to $4, indicating a less optimistic outlook for the company.
September 13, 2024 | 11:39 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
HC Wainwright & Co. has downgraded Fulcrum Therapeutics from Buy to Neutral and significantly lowered the price target from $17 to $4, suggesting a negative outlook.
The downgrade from Buy to Neutral and the drastic reduction in price target from $17 to $4 by HC Wainwright & Co. indicates a significant shift in the analyst's outlook on Fulcrum Therapeutics. This is likely to negatively impact the stock price in the short term as investors react to the less favorable assessment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100